PLD3 Antibody

Research Applications and Findings

PLD3 antibodies have been instrumental in elucidating the protein’s biological roles:

Role in Alzheimer’s Disease (AD)

• Genetic Association: Rare coding variants in PLD3 (e.g., V232M) are linked to a two-fold increased risk for late-onset AD . PLD3 expression is reduced in AD brains compared to controls ($p = 8.10 \times 10^{-10}$) .

• Amyloid-Beta Regulation: Overexpression of PLD3 decreases intracellular amyloid precursor protein (APP) and extracellular Aβ42/Aβ40 levels, while PLD3 knockdown elevates Aβ peptides .

• Axonal Pathology: Neuronal overexpression of PLD3 exacerbates endolysosomal vesicle accumulation in axonal spheroids, contributing to Aβ42 uptake and conduction blockades in AD models .

Lysosomal and Cellular Functions

• PLD3 localizes to intraluminal vesicles (ILVs) of multivesicular bodies (MVBs) and lysosomes, influencing endolysosomal maturation and autophagic degradation .

• It acts as a 5' exonuclease, degrading mitochondrial DNA (mtDNA) in antigen-presenting cells to prevent TLR9/STING-mediated inflammation .

Myogenesis and Neurogenesis

• PLD3 enhances myotube formation in vitro and modulates insulin signaling by inhibiting Akt phosphorylation .

• It contributes to late-stage neurogenesis, including neuronal survival and synaptic connectivity .

Key Research Insights

Controversies and Limitations

While PLD3 is implicated in AD, some studies question its pathogenicity. For example, its role in APP processing is debated, as PLD3 overexpression in mice did not alter amyloid plaque burden . Additionally, its enzymatic activity remains poorly characterized compared to PLD1/2 .